SCHEMBL215369

SCHEMBL215369

CC(=O)c1ccccc1N(C(=O)c1nc[nH]c1C(N)=O)c1nc2ccccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
NR4A1 P22736 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HPGD P15428 2/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 5/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
PARP1 P09874 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
HIF1A Q16665 1/20 0.34
PAX8 Q06710 2/20 0.33
EGFR P00533 1/20 0.33
CYP3A4 P08684 1/20 0.33
KDM4E B2RXH2 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214715 0.88 POLB (0.40) POLBRAB9ASMN1; SMN2NPC1NR4A1
SCHEMBL214873 0.86 LMNA (0.39) POLBRAB9ASMN1; SMN2NPC1NR4A1
SCHEMBL214647 0.86 POLB (0.38) POLBRAB9ANPC1TDP1HPGD
SCHEMBL216075 0.85 POLB (0.38) POLBSMN1; SMN2HPGDHTTLMNA
SCHEMBL213504 0.85 POLB (0.38) POLBRAB9ASMN1; SMN2NPC1NR4A1
SCHEMBL215596 0.85 POLB (0.38) POLBRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL214273 0.85 POLB (0.38) POLBRAB9ASMN1; SMN2NPC1NR4A1
SCHEMBL215645 0.85 POLB (0.37) POLBRAB9ATDP1HPGDHTT
SCHEMBL213330 0.85 POLB (0.37) POLBRAB9ASMN1; SMN2NPC1NR4A1
SCHEMBL214790 0.84 HPGD (0.37) POLBRAB9ASMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885RAB9A 2213/4885SMN1; SMN2 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.